1. Short title This Act may be cited as the Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act . 2. Exclusivity to encourage development of novel therapies targeting serious microbial infections Subchapter B of chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360aa et seq.) is amended by inserting after section 529A the following: 530. Exclusivity to encourage development of novel therapies targeting serious microbial infections (a) In general If the Secretary approves an application pursuant to section 505(c) of this Act or section 351(a) of the Public Health Service Act for a drug that has been designated as a priority antimicrobial product under subsection (k), the Secretary shall award to the holder of the application a 12-month exclusivity extension period described in subsection (c) for the sole purpose of conveying such extension, in whole or in portions, to other sponsors or holders to be applied with respect to one or more other drugs— (1) for which an application is submitted under section 505(b)(1); (2) for which at approval, new chemical entity exclusivity is granted under subsection (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505; and (3) that is designated as a fast track product under section 506(b). (b) Notice to Secretary Upon making a conveyance under subsection (a), the holder of the approved application for the priority antimicrobial product involved shall submit a notice to the Secretary including— (1) the name of the priority antimicrobial product; (2) the name of the recipient drug